Kun He, PhD

Liposomal Doxorubicin in Combination With Bortezomib for Relapsed or Refractory Multiple Myeloma

November 1, 2007

Yang-Min Ning, MD, PhD
Kun He, PhD
Ramzi Dagher, MD
Rajeshwari Sridhara, PhD
Ann Farrell, MD
Robert Justice, MD
Richard Pazdur, MD

Liposomal doxorubicin received FDA approval for use in combination with bortezomib in patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.

READ >>
Add new comment

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?